semaglutide and a1c Is Weight Loss the Main Driver for Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice - Al‐Badri - 2025 Oral "ozempic" lowers A1c and

Ethics declarations Conflict of interest The authors declare no conflict of interests

If you have a significant amount of weight to lose and no contraindications to tirzepatide, the superior efficacy data makes it a strong candidate

For example, looking at Zepbound vials, you might see that a 7.5 mg dose comes in a 0.5 mL volume, and this 0.5 mL often corresponds to 50 units on your injection pen

They are a bit heavy on the updates but I'd rather have more communication than less

Tools like short surveys during appointments, secure portal updates, and follow-up calls after dose changes can create a framework for consistent monitoring and timely intervention